Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Pathological Aggression (AHIMSA-1)
NCT02989779Phase 2Unknown
- Sponsor
- St. Joseph's Healthcare Hamilton
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aprepitant in intermittent explosive disorder (IED), disruptive mood dysregulation disorder (DMDD), sponsored by St. Joseph's Healthcare Hamilton. Status: unknown.
02
Drugs
aprepitant
03
Conditions
intermittent explosive disorder (IED)disruptive mood dysregulation disorder (DMDD)
Beyond the preview
Go deeper on NCT02989779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989779.